Bourbon - But not sure if there would be issues of each trying to sell into the other's market.
I don't think so. Biogen will add A2-73 to their MS drug of choice (should have zero impact on AD) and Pfizer will add A2-73 to Aricept...unless Biogen wants to add A2-73 to their lead AD drug...then this where it can get tricky...I suspect we will license each separately. unless someone decides to pay a lot upfront for it all.